Quinoline

Quinoline

SCHEMBL2058675

NN.c1ccc2ncccc2c1

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.90
MAPT P10636 4/20 0.56
HTT P42858 3/20 0.56
KDM4E B2RXH2 3/20 0.56
CASP1 P29466 2/20 0.56
TP53 P04637 2/20 0.56
HSP90AA1 P07900 2/20 0.56
TSHR P16473 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
ATM Q13315 2/20 0.56
HSP90AB1 P08238 1/20 0.56
HSD17B10 Q99714 1/20 0.56
NPC1 O15118 3/20 0.54
RAB9A P51151 2/20 0.54
POLB P06746 1/20 0.54
CYP3A4 P08684 2/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CASP7 P55210 1/20 0.50
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL1270969 0.95 ALDH1A1 (1.00) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL29822171 0.95 ALDH1A1 (1.00) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL2774 0.95 ALDH1A1 (1.00) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL32661377 0.95 ALDH1A1 (1.00) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL29349552 0.95 ALDH1A1 (1.00) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL3848658 0.92 ALDH1A1 (0.85) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL2313500 0.92 ALDH1A1 (0.85) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL23202414 0.92 ALDH1A1 (0.94) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL5422407 0.92 ALDH1A1 (0.94) ALDH1A1MAPTHTTKDM4ECASP1
Quinoline SCHEMBL6381814 0.92 ALDH1A1 (0.94) ALDH1A1MAPTHTTKDM4ECASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184681-A Spiro 1,2, 4-triazole carbene metal complex, intermediate, preparation method and application thereof 浙江工业大学 2024-06-14 CN disclosed
CN-114349656-B Preparation method of hydrazide compound 赣南师范大学 2024-03-29 CN disclosed
CN-114349656-A Preparation method of hydrazide compound 赣南师范大学 2022-04-15 CN disclosed
CN-112300173-B Nitrogen-containing polycyclic compounds, preparation method and application 上海凌达生物医药有限公司 2021-10-01 CN disclosed
CN-112300173-A Nitrogen-containing polycyclic compounds, preparation method and application 上海凌达生物医药有限公司 2021-02-02 CN disclosed
CN-104704366-B Azaindole quinoline-the cyanine dye and its bioconjugates of hydroxamic acid substitution 贝克顿·迪金森公司 2018-06-19 CN disclosed
EP-2912464-A1 HYDROXAMATE SUBSTITUTED AZAINDOLINE-CYANINE DYES AND BIOCONJUGATES OF THE SAME Becton Dickinson and Company (US) 2015-09-02 EP disclosed
CN-104704366-A Hydroxamate substituted azaindoline-cyanine dyes and bioconjugates of the same BECTON DICKINSON CO 2015-06-10 CN disclosed
WO-2014066552-A1 HYDROXAMATE SUBSTITUTED AZAINDOLINE-CYANINE DYES AND BIOCONJUGATES OF THE SAME BECTON, DICKINSON AND COMPANY (US) 2014-05-01 WO disclosed
CN-103335880-A Method for separating and enriching carbadox and chlorpromazine in water CHINESE RES ACAD ENV SCIENCES 2013-10-02 CN disclosed
EP-2201070-A2 AZO QUINOLINIUM COMPOUNDS COMPRISING A DISULPHIDE/THIOL UNIT, COMPOSITIONS CONTAINING SAME, PROCESS FOR DYEING KERATIN FIBRES AND DEVICE L'Oreal (FR) 2010-06-30 EP disclosed
WO-2009034059-A2 AZO QUINOLINIUM COMPOUNDS COMPRISING A DISULPHIDE/THIOL UNIT, COMPOSITIONS CONTAINING SAME, PROCESS FOR DYEING KERATIN FIBRES AND DEVICE L'OREAL (FR) 2009-03-19 WO disclosed
CN-1204216-C Anti-alkali smelting combined epoxy modified powder paint INST METAL RES CHINESE ACAD SC (CN) 2005-06-01 CN disclosed
CN-1511905-A Anti-alkali smelting combined epoxy modified powder paint 中国科学院金属研究所 2004-07-14 CN disclosed
US-20040105614-A1 Optical switching element and photoaddressable display medium using the same FUJI XEROX CO., LTD. (JP) 2004-06-03 US disclosed
US-20030219377-A1 Compounds and methods for diagnosing and treating amyloid-related conditions PHARMACIA & UPJOHN COMPANY 2003-11-27 US disclosed
US-6589504-B1 Binding or aggregating fibrils with radiolabeled quinoline-hydrazone compound PHARMACIA & UPJOHN COMPANY 2003-07-08 US disclosed
EP-1318982-A1 COMPOUNDS AND METHODS FOR DIAGNOSING AND TREATING AMYLOID-RELATED CONDITIONS PHARMACIA & UPJOHN COMPANY (US) 2003-06-18 EP disclosed
WO-2002024652-A1 COMPOUNDS AND METHODS FOR DIAGNOSING AND TREATING AMYLOID-RELATED CONDITIONS PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 WO disclosed
US-4407803-A ANTIASTHMA, ANTI-RHEUMATOID ARTHRITIS ABBOTT LABORATORIES (US) 1983-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030219377-A1 Compounds and methods for diagnosing and treating amyloid-related conditions APP, IAPP, HTT ALDH1A1 694/4885MAPT 13/4885HTT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.